Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Chomienne

Showing results (131-140 of 151) with videos related to

Pageof 16
Sort By:
Leukemia|November 11, 2006
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myelomaB Arnulf, S Lecourt, J Soulier, et al.
Nucleic Acids Research|January 29, 2002
Retinoic acid receptor alpha1 variants, RARalpha1DeltaB and RARalpha1DeltaBC, define a new class of nuclear receptor isoformsA Parrado, G Despouy, R Kraïba, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
All trans retinoic acid abrogates spontaneous monocytic growth in juvenile chronic myelomonocytic leukaemiaN Cambier, M L Menot, M H Schlageter, et al.
Blood Cancer Journal|December 15, 2015
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia miceS Patel, L Guerenne, P Gorombei, et al.
Leukemia|December 9, 1998
Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemiaP Bolufer, E Barragán, M A Sánz, et al.
Cell Death & Disease|August 14, 2015
AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineagesE Six, C Lagresle-Peyrou, S Susini, et al.
Leukemia|August 26, 2016
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemiaS Ganesan, A A Alex, E Chendamarai, et al.
Leukemia|October 24, 2013
Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatmentS Hasan, B Cassinat, N Droin, et al.
Leukemia|July 1, 2017
Preclinical modeling of myelodysplastic syndromesK Rouault-Pierre, S A Mian, M Goulard, et al.
Journal of Medical Genetics|June 15, 2010
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemiaB Pérez, F Mechinaud, C Galambrun, et al.
Pageof 16

Showing results (131-140 of 151) with videos related to

Sort By:
Pageof 16
Leukemia|November 11, 2006
Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myelomaB Arnulf, S Lecourt, J Soulier, et al.
Nucleic Acids Research|January 29, 2002
Retinoic acid receptor alpha1 variants, RARalpha1DeltaB and RARalpha1DeltaBC, define a new class of nuclear receptor isoformsA Parrado, G Despouy, R Kraïba, et al.
The Hematology Journal : the Official Journal of the European Haematology Association|June 26, 2001
All trans retinoic acid abrogates spontaneous monocytic growth in juvenile chronic myelomonocytic leukaemiaN Cambier, M L Menot, M H Schlageter, et al.
Blood Cancer Journal|December 15, 2015
pVAX14DNA-mediated add-on immunotherapy combined with arsenic trioxide and all-trans retinoic acid targeted therapy effectively increases the survival of acute promyelocytic leukemia miceS Patel, L Guerenne, P Gorombei, et al.
Leukemia|December 9, 1998
Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemiaP Bolufer, E Barragán, M A Sánz, et al.
Cell Death & Disease|August 14, 2015
AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineagesE Six, C Lagresle-Peyrou, S Susini, et al.
Leukemia|August 26, 2016
Rationale and efficacy of proteasome inhibitor combined with arsenic trioxide in the treatment of acute promyelocytic leukemiaS Ganesan, A A Alex, E Chendamarai, et al.
Leukemia|October 24, 2013
Use of the 46/1 haplotype to model JAK2(V617F) clonal architecture in PV patients: clonal evolution and impact of IFNα treatmentS Hasan, B Cassinat, N Droin, et al.
Leukemia|July 1, 2017
Preclinical modeling of myelodysplastic syndromesK Rouault-Pierre, S A Mian, M Goulard, et al.
Journal of Medical Genetics|June 15, 2010
Germline mutations of the CBL gene define a new genetic syndrome with predisposition to juvenile myelomonocytic leukaemiaB Pérez, F Mechinaud, C Galambrun, et al.
Pageof 16